Volume 89, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Treating drug-resistant tuberculosis (DR-TB) is particularly challenging in high human immunodeficiency virus (HIV) prevalence settings. Neither antiretroviral resistance testing nor viral load monitoring is widely available in sub-Saharan Africa, and antiretroviral resistance can complicate the clinical management for DR-TB/HIV coinfected patients. We describe six cases of antiretroviral resistance in DR-TB patients with HIV coinfection in Lesotho. Two patients died before or immediately after antiretroviral resistance was detected by genotyping; the remaining four patients were switched to effective antiretroviral therapy (ART) regimens. Favorable DR-TB treatment outcomes in coinfected patients require successful management of their HIV infection, including treatment with an effective ART regimen. Coinfected patients undergoing DR-TB treatment may require closer monitoring of their response to ART, including routine viral load testing, to ensure that they receive an effective ART regimen concurrent with DR-TB treatment.


Article metrics loading...

Loading full text...

Full text loading...



  1. World Health Organization, UNAIDS, UNICEF, 2011. Global HIV/AIDS Response: Epidemic Update and Health Sector Progress towards Universal Access, Progress Report 2011. Geneva: World Health Organization.
  2. World Health Organization, 2011. Towards Universal Access to Diagnosis and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis by 2015: WHO Progress Report 2011. Geneva: World Health Organization.
  3. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, Botes ME, Wellington M, Osibogun A, Sigaloff KC, Nankya I, Schuurman R, Wit FW, Stevens WS, van Vugt M, de Wit TF, , 2011. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 11: 750759.[Crossref]
  4. World Health Organization, 2011. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update. Geneva: World Health Organization.
  5. Brust JC, Gandhi NR, Carrara H, Osburn G, Padayatchi N, , 2010. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000–2003. Int J Tuberc Lung Dis 14: 413419.
  6. Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, Satti H, , 2009. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in southern Africa. PLoS One 4: e7186.[Crossref]
  7. World Health Organization, 2010. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Recommendations for a Public Health Approach: 2010 Revision. Geneva: World Health Organization.
  8. McIlleron H, Meintjes G, Burman WJ, Maartens G, , 2007. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 196 (Suppl 1): S63S75.[Crossref]
  9. Jones BE, Oo MM, Taikwel EK, Qian D, Kumar A, Maslow ER, Barnes PF, , 1997. CD4 cell counts in human immunodeficiency virus-negative patients with tuberculosis. Clin Infect Dis 24: 988991.[Crossref]
  10. Reynolds SJ, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, Boaz I, Quinn TC, Gray R, Wawer M, Serwadda D, , 2009. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 23: 697700.[Crossref]
  11. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP, , 2009. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 9: 153161.[Crossref]
  12. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, Brumme CJ, Brumme ZL, Mo T, Alexander CS, Montaner JS, , 2005. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 191: 339347.[Crossref]
  13. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Padmapriyadarsini C, Swaminathan S, Venkatesan P, Sekar L, Kumar S, Krishnarajasekhar OR, Paramesh P, , 2004. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis 38: 280283.[Crossref]
  14. Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, Goemaere E, Coetzee D, Maartens G, , 2008. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 300: 530539.[Crossref]
  15. Panel on Antiretroviral Guidelines for Adults and Adolescents, 2012. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed January 24, 2013.
  16. Maartens G, Decloedt E, Cohen K, , 2009. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther 14: 10391043.[Crossref]
  17. Stanford University, 2012. Stanford University HIV Drug Resistance Database. Stanford University, 2012. Available at: http://hivdb.stanford.edu/. Accessed March 26, 2013.
  18. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, Wensing AM, Richman DD, , 2011. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 19: 156164.
  19. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, Zarovska E, Rich ML, Fraser HS, Alarcon E, Cegielski JP, Grzemska M, Gupta R, Espinal M, , 2005. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 9: 640645.

Data & Media loading...

  • Received : 23 Jan 2013
  • Accepted : 06 Apr 2013

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error